Effect of photobiomodulation therapy on radiodermatitis in a mouse model: an experimental animal study
- PDF / 2,037,729 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 37 Downloads / 207 Views
ORIGINAL ARTICLE
Effect of photobiomodulation therapy on radiodermatitis in a mouse model: an experimental animal study Ji-Hye Park 1 & Hyun Jeong Byun 1 & Hyun Je Kim 1 & Se Jin Oh 1 & Changhoon Choi 2 & Jae Myung Noh 2 & Dongryul Oh 2 & Jong-Hee Lee 1 & Dong-Youn Lee 1 Received: 14 May 2020 / Accepted: 10 August 2020 # Springer-Verlag London Ltd., part of Springer Nature 2020
Abstract This study aimed to evaluate the effect of photobiomodulation (PBM) for prevention of radiodermatitis in an irradiated mouse model and compare the efficacy of PBM using 633- or 830-nm wavelengths. Irradiated mice were randomly distributed into three groups: A (633 nm), B (830 nm), and C (without PBM). On post-irradiation days 7 and 21, we compared acute damage and recovery in treated skin samples to non-irradiated skin using H&E, Masson’s trichrome, anti-CD45 and PCNA immunohistochemistry, and a TUNEL assay. Grade 3 radiodermatitis was evident only in group C. Compared with that in group C, the skin in groups A and B had significantly less epidermal hyperplasia, inflammatory cell infiltration, and thinner dermis on day 7 and less inflammatory cell infiltration, fewer apoptotic cells, and thinner dermis on day 21. However, there was no significant difference between groups A and B. This study indicates PBM could prevent severe radiodermatitis by reducing epidermal and dermal damage, inflammation, and apoptosis. There was no difference in PBM efficacy between the 633- and 830-nm wavelengths. Keywords Laser . Low-level laser therapy . Photobiomodulation . Prevention . Radiodermatitis . Skin
Abbreviations BALB/c Bagg Albino/c CD45 Cluster of differentiation 45 H&E Hematoxylin and eosin LED Light-emitting diodes MT Masson’s trichrome PBM Photobiomodulation PBMT Photobiomodulation therapy PBS Phosphate-buffered saline PCNA Proliferating cell nuclear antigen Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10103-020-03123-x) contains supplementary material, which is available to authorized users. * Ji-Hye Park [email protected] 1
Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, #81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea
2
Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
RT SAS TUNEL TGF-β
Radiation therapy Statistical analysis system Terminal deoxynucleotidyl transferase–mediated dUTP nick-end labeling Transforming growth factor-beta
Introduction Photobiomodulation (PBM), also known as low-level laser or light therapy (LLLT), was introduced by the Hungarian physician and surgeon, Endre Mester, in 1967. Mester accidentally discovered that low-level ruby laser (694 nm) illumination stimulated hair regrowth during an attempt to replicate experiments which had shown that such lasers could reduce tumors in mice [1]. Mester called this effect “laser biostimulation” and subsequently used a HeNe laser (632.8 nm) to stimulate wound healing in an animal
Data Loading...
